Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?


Autoria(s): Borba, Eduardo F.; Saad, Carla G. S.; Pasoto, Sandra G.; Calich, Ana L. G.; Aikawa, Nadia E.; Ribeiro, Ana C. M.; Moraes, Julio C. B.; Leon, Elaine P.; Costa, Luciana P.; Guedes, Lissiane K. N.; Silva, Clovis A. A.; Goncalves, Celio R.; Fuller, Ricardo; Oliveira, Suzimara A.; Ishida, Maria A.; Precioso, Alexander R.; Bonfa, Eloisa
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/10/2013

21/10/2013

2012

Resumo

Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens. Methods. A total of 555 SLE patients and 170 healthy controls were vaccinated with a single dose of a non-adjuvanted preparation. According to current therapy, patients were initially classified as SLE No Therapy (n = 75) and SLE with Therapy (n = 480). Subsequent evaluations included groups under monotherapy: chloroquine (CQ) (n = 105), prednisone (PRED) epsilon 20 mg (n = 76), immunosuppressor (IS) (n = 95) and those with a combination of these drugs. Anti-H1N1 titres and seroconversion (SC) rate were evaluated at entry and 21 days post-vaccination. Results. The SLE with Therapy group had lower SC compared with healthy controls (59.0 vs 80.0%; P < 0.0001), whereas the SLE No Therapy group had equivalent SC (72 vs 80.0%; P = 0.18) compared with healthy controls. Further comparison revealed that the SC of SLE No Therapy (72%) was similar to the CQ group (69.5%; P = 0.75), but it was significantly reduced in PRED epsilon 20 mg (53.9%; P = 0.028), IS (55.7%; P = 0.035) and PRED epsilon 20 mg + IS (45.4%; P = 0.038). The concomitant use of CQ in each of these later regimens was associated with SC responses comparable with SLE No Therapy group (72%): PRED epsilon 20 mg + CQ (71.4%; P = 1.00), IS + CQ (65.2%; P = 0.54) and PRED epsilon 20 mg + IS + CQ (57.4%; P = 0.09). Conclusion. Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/51897-5, 2010/10749-0]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [303165/2008-1, 300248/2008-3, 301411/2009-3]

Federico Foundation

Federico Foundation

Butantan Foundation

Butantan Foundation

Identificador

RHEUMATOLOGY, OXFORD, v. 51, n. 6, supl. 4, Part 1-2, pp. 1061-1069, JUN, 2012

1462-0324

http://www.producao.usp.br/handle/BDPI/35177

10.1093/rheumatology/ker427

http://dx.doi.org/10.1093/rheumatology/ker427

Idioma(s)

eng

Publicador

OXFORD UNIV PRESS

OXFORD

Relação

RHEUMATOLOGY

Direitos

closedAccess

Copyright OXFORD UNIV PRESS

Palavras-Chave #SYSTEMIC LUPUS ERYTHEMATOSUS #VACCINE #INFECTION #INFLUENZA #ANTIMALARIALS #DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS #IMMUNOSUPPRESSIVE #H1N1 VACCINATION #IMMUNE RESPONSE #EFFICACY #PREVENTION #SYSTEMIC-LUPUS-ERYTHEMATOSUS #HUMORAL IMMUNE-RESPONSE #RHEUMATIC-DISEASES #MALARIA CHEMOPROPHYLAXIS #ANTIBODY-RESPONSE #IN-VIVO #SAFETY #CHLOROQUINE #IMMUNIZATION #RECOMMENDATIONS #RHEUMATOLOGY
Tipo

article

original article

publishedVersion